Pharmaceuticals

Global Hereditary Angioedema Therapeutics Market Forecast 2026–2035: Long-Term Growth Insights

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the hereditary angioedema therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Hereditary Angioedema Therapeutics Market in 2030?

The hereditary angioedema therapeutics market size has shown substantial growth in recent years. It is forecast to expand from $7.77 billion in 2025 to $9.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.3%. This historical expansion can be attributed to several factors, including limited awareness about HAE, a reliance on hospital-based therapies, a scarcity of approved treatment options, the predominant use of intravenous administration, and low prevalence diagnosis rates.

The hereditary angioedema therapeutics market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $19.03 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 19.7%. This growth over the forecast period is driven by factors such as the rise in recombinant C1 esterase inhibitors, the adoption of subcutaneous delivery methods, increased utilization of prophylactic therapies, the expansion of specialty pharmacy channels, and greater investment in rare disease research. Prominent trends for the forecast period encompass the development of personalized therapies, a surge in orphan drug approvals, advancements in subcutaneous drug delivery, the emergence of on-demand treatment options, and the broadening of hospital and retail pharmacy networks.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Drivers Are Influencing Production Trends In The Hereditary Angioedema Therapeutics Market?

Future expansion of the hereditary angioedema therapeutics market is anticipated, driven by the rising expenditure on healthcare. This expenditure represents the complete sum of resources, particularly financial, allocated to healthcare products and services over a defined timeframe in a particular region. Higher healthcare spending facilitates greater investment into research and development efforts aimed at uncovering the root causes of hereditary angioedema and creating novel treatment options. For example, data from June 2025 by the Centers for Medicare & Medicaid Services (CMS), a federal agency in the US, indicated that the National Health Expenditure (NHE) reached $4.9 trillion in 2023, growing by 7.5% or $14,570 per person, and constituting 17.6% of the Gross Domestic Product (GDP). Hospital spending specifically saw a 10.4% increase, reaching $1,519.7 billion in 2023, which surpassed the 3.2% growth observed in 2022. Consequently, the expanding healthcare expenditure is propelling the expansion of the hereditary angioedema therapeutics market.

Which Segment Groups Are Influencing The Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-Demand

How Are New Market Trends Shaping The Landscape Of The Hereditary Angioedema Therapeutics Market?

Leading companies within the hereditary angioedema (HAE) therapeutics market are innovating new treatments, specifically oral plasma kallikrein inhibitors, to improve patient management and deliver effective, immediate options for relieving HAE attacks, thereby enhancing overall patient outcomes and their quality of life. These oral plasma kallikrein inhibitors are medications taken by mouth that work by inhibiting the enzyme plasma kallikrein, thus helping to manage and lessen the severity of hereditary angioedema attacks. For example, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, secured US Food and Drug Administration approval for a New Drug Application for Sebetralstat, intending to provide HAE patients with a more convenient, non-invasive treatment alternative to intravenous or subcutaneous drugs. This offering fulfills the increasing demand for quick, efficient oral treatments that can be given instantly during an hereditary angioedema attack.

Who Are The Major Companies Operating In The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hereditary Angioedema Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795